EP Patent

EP1817041A2 — Tafi inhibitors and their use to treat pulmonary fibrosis

Assigned to Bayer Pharma AG · Expires 2007-08-15 · 19y expired

What this patent protects

The invention relates to TAFI inhibitors and their use to treat pulmonary fibrosis.

USPTO Abstract

The invention relates to TAFI inhibitors and their use to treat pulmonary fibrosis.

Drugs covered by this patent

Patent Metadata

Patent number: EP1817041A2
Jurisdiction: EP
Classification: —
Expires: 2007-08-15
Drug substance claim: No
Drug product claim: No
Assignee: Bayer Pharma AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.